This post will explore the role of anti-VEGF injections in the management of proliferative diabetic retinopathy. It will cover the effect of anti-VEGF on diabetic retinal neovascularization and vitreous haemorrhage. It will also address the common concerns regarding the use of anti-VEGF in proliferative disease, including the risk of tractional retinal detachment (crunch) and the danger in loss to follow up.

This is a discussion of the role of anti-VEGF injections in the treatment of moderate to severe non-proliferative diabetic retinopathy without macula oedema

Many patients with neovascular AMD are on anti-coagulation. This piece will discuss the risk factors of haemorrhage in neovascular AMD, and explore if anti-coagulation will affect the risk of macula haemorrhage

A discussion on the causes of vision loss for patients with neovascular AMD treated with anti-VEGF, and how this can inform future treatment decisions.

A discussion on the latest data available regarding the risk of recurrence in neovascular age related macula degeneration following cessation of anti-VEGF injections

Are these injections for life, or can they be stopped at some point?

A short presentation by Dr Sheck on the risk of vision loss with delays in anti-VEGF injections for neovascular AMD. This is of particular relevance during the COVID-19 pandemic.